Bayesian methods for expression-based integration of various types of genomics data Computational methods for biomarker discovery and systems biology research

Eurasip Journal on Bioinformatics and Systems Biology

Volumn 2013, Issue 1, 2013, Pages

  Jennings, Elizabeth M ^a   Morris, Jeffrey S ^b   Carroll, Raymond J ^a   Manyam, Ganiraju C ^b   Baladandayuthapani, Veerabhadran ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bayesian modeling; Genomics; Hierarchical models; Integrative analysis; Shrinkage priors

Indexed keywords

BAYESIAN NETWORKS; HIERARCHICAL SYSTEMS; SHRINKAGE;

BAYESIAN MODEL; BIOLOGICAL RELATIONSHIPS; GENOMICS; GLIOBLASTOMA MULTIFORME; HIERARCHICAL BAYESIAN ANALYSIS; HIERARCHICAL MODEL; INTEGRATIVE ANALYSIS; SHRINKAGE ESTIMATIONS;

GENE EXPRESSION;

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; SOMATOMEDIN C RECEPTOR;

ARTICLE; BAYES THEOREM; CANCER GENETICS; CANCER PROGNOSIS; GENE EXPRESSION; GENOME ANALYSIS; GENOMICS; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; TUMOR SUPPRESSOR GENE;

EID: 84887049272     PISSN: 16874145     EISSN: 16874153     Source Type: Journal    
DOI: 10.1186/1687-4153-2013-13     Document Type: Article

References (41)

1. Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C: Glioblastoma multiforme oncogenomics and signaling pathways. Clin. Med. Oncol 2009, 3:39-52.
2. Pathway analysis of genetic alterations in glioblastoma (TCGA) http://cbio.mskcc.org/cancergenomics/gbm/pathways/ 2012. [Memorial Sloan-Kettering Cancer Center]. Accessed 9 August 2012.
3. Program overview http://cancergenome.nih.gov/abouttcga/overview 2012. [The Cancer Genome Atlas]. Accessed 9 August 2012
4. Wang W, Baladandayuthapani V, Morris JS, Broom BM, Manyam G, Do KA: iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data. Bioinformatics 2013,29(2):149-159.
5. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin A, Gross J, Hartmann L, Huang M, Huntsman D, Iacocca M, Imielinski M, Kalloger S, Karlan B, Levine D, Mills G, Morrison C, Mutch D, Olvera N, Orsulic S, Park K, Petrelli N, Rabeno B, Rader J, Sikic B, et al.: Integrated genomic analyses of ovarian carcinoma. Nature 2011,474(7353):609-615.
6. McR endon L, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, Yung WK, Bogler O, Weinstein JN, VandenBerg S, Berger M, Prados M, Muzny D, Morgan M, Scherer S, Sabo A, Nazareth L, Lewis L, Hall O, Zhu Y, Ren Y, Alvi O, Yao J, Hawes A, Jhangiani S, Fowler G, et al.: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008,455(7216):1061-1068.
7. Shen R, Olshen AB, Ladanyi M: Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 2009,25(22):2906-2912.
8. Tyekucheva S, Marchionni L, Karchin R, Parmigiani G: Integrating diverse genomic data using gene sets. Genome Biol 2011,12(10):R105.
9. Lanckriet GR, De Bie T, Cristianini N, Jordan MI, Noble WS: A statistical framework for genomic data fusion. Bioinformatics 2004,20(16):2626-2635. (Pubitemid 39530149)
10. Liu D, Lin X, Ghosh D: Semiparametric regression of multi-dimensional genetic pathway data: least squares kernel machines and linear mixed models. Biometrics 2007, 63:1079-1088. (Pubitemid 350212565)
11. Griffin JE, Brown PJ: Inference with normal-gamma prior distributions in regression problems. Bayesian Anal 2010, 5:171-188.
12. Wei LJ: The accelerated failure time model: A useful alternative to the cox regression model in survival analysis. Stat Med 1992,11(14-15):1871-1879. [ http://dx.doi.org/10.1002/sim.4780111409 ]. (Pubitemid 23015636)
13. Park T, Casella G: The Bayesian lasso. J Am. Stat. Assoc 2008,103(482):681-686.
14. Tibshirani R: Regression shrinkage and selection via the lasso. J. R. Stat Soc. Series B (Methodological) 1996, 58:267-288.
15. Griffin JE, Brown PJ: Structuring shrinkage: some correlated priors for regression. Biometrika 2012,99(2):481-487. [ http://EconPapers.repec.org/RePEc: oup:biomet:v:99:y:2012:i:2:p:481-487 ].
16. Barbieri MM, Berger JO: Optimal predictive model selection. Ann. Stat 2004,32(3):870-897. (Pubitemid 41250287)
17. American Cancer Society: American Cancer Society: Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
18. Glioblastoma http://www.abta.org/understanding-brain-tumors/types-of- tumors/glioblastoma.html 2013. [American Brain Tumor Association]. Accessed 6 June 2013
19. Johnson DR, O'Neill BP: Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol 2012,107(2):359-364.
20. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, et al.: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in, PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
21. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010,17(5):510-522.
22. Data levels and data types https://tcga-data.nci.nih.gov/tcga/ tcgaDataType.jsp. [TCGA]. Accessed 22 August 2013
23. Loilome W, Joshi AD, ap Rhys CM, Piccirillo S, Vescovi AL, Angelo VL, Gallia GL, Riggins GJ: Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling. J. Neurooncol 2009,94(3):359-366.
24. Katoh M, Nakagama H: FGF Receptors: Cancer Biology and Therapeutics. Rev. Med. Res 2013. doi:10.1002/med.21288
25. Goldstein M, Meller I, Orr-Urtreger A: FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes Cancer 2007,46(11):1028-1038. (Pubitemid 47502842)
26. Carapancea M, Alexandru O, Fetea AS, Dragutescu L, Castro J, Georgescu A, Popa-Wagner A, Backlund ML, Lewensohn R, Dricu A: Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J. Neurooncol 2009,92(2):137-147.
27. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207. (Pubitemid 34074005)
28. Hewish M, Chau I, Cunningham D: Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov 2009, 4:54-72.
29. Ruano Y, Mollejo M, Ribalta T, Fiano C, Camacho FI, Gomez E, de Lope AR, Hernandez-Moneo JL, Martinez P, Melendez B: Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol. Cancer 2006, 5:39. (Pubitemid 44541842)
30. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu G, Kato M, Sanada M, Jauch A, Dugas M, Black KL, Koeffler HP: High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol. Cancer Res 2009,7(5):665-677.
31. Rebocho AP, Marais R: ARAF acts as a scaffold to stabilize BRAF: CRAF heterodimers. Oncogene 2013,32(26):3207-3212.
32. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD: Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol. Cancer Ther 2013, 12:104-116.
33. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992,70(3):431-442.
34. Kapoor GS, O'Rourke DM: SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration. Oncogene 2010,29(29):4130-4144.
35. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol. Chem 1996,271(41):25639-25645. (Pubitemid 26337944)
36. Solomon DA, Kim JS, Jenkins S, Ressom H, Huang M, Coppa N, Mabanta L, Bigner D, Yan H, Jean W, Waldman T: Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 2008,68(8):2564-2569. (Pubitemid 351556252)
37. Nazarenko I, Hede SM, He X, Hedren A, Thompson J, Lindstrom MS, Nister M: PDGF and PDGF receptors in glioma. Ups. J. Med. Sci 2012,117(2):99-112.
38. Suzuki K, Momota H, Tonooka A, Noguchi H, Yamamoto K, Wanibuchi M, Minamida Y, Hasegawa T, Houkin K: Glioblastoma simultaneously present with adjacent meningioma: case report and review of the literature. J. Neurooncol 2010, 99:147-153.
39. Jiang Y, Boije M, Westermark B, Uhrbom L: PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia 2011,13(6):492-503.
40. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, Saltz JH, Brat DJ, Moreno CS: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE 2010,5(9):e12548.
41. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E: Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 2009,4(11):e7752.